Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Lipid Losses: National Data Show Drastic Drops in Total Cholesterol, Triglycerides, and LDL

Yael L. Maxwell

November 30, 2016

News Conference News

You Can’t Blame Your Genes: Healthy Lifestyle Halves Genetic Risk of CAD

Shelley Wood

November 15, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

Los Niveles de CRP Puede Identificar Riesgos CV Bajos en Pacientes Obesos Metabólicamente ‘Sanos’

L.A. McKeown

June 13, 2016

News Daily News

CRP 可以用于识别代谢“健康”的肥胖患者的低心血管风险

L.A. McKeown

June 13, 2016

News Daily News

CRP Can Identify Low CV Risk in Metabolically ‘Healthy’ Obese Patients

L.A. McKeown

June 13, 2016

News Conference News EAS 2016

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

Yael L. Maxwell

May 31, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

Advertisement

Lipid Losses: National Data Show Drastic Drops in Total Cholesterol, Triglycerides, and LDL

You Can’t Blame Your Genes: Healthy Lifestyle Halves Genetic Risk of CAD

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Los Niveles de CRP Puede Identificar Riesgos CV Bajos en Pacientes Obesos Metabólicamente ‘Sanos’

CRP 可以用于识别代谢“健康”的肥胖患者的低心血管风险

CRP Can Identify Low CV Risk in Metabolically ‘Healthy’ Obese Patients

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content